BerGenBio Virtual R&D Day - 06 November 2020
Saturday, October 31, 2020
BERGEN, Norway, Oct. 23, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET.
The event will feature independent experts highlighting the role of AXL kinase as an essential mediator of the biological mechanisms underlying life-threatening diseases. The presentations will focus on the role of AXL in specific disease areas including oncology, fibrosis and infectious disease such as COVID-19. Each presentation will be followed by a Q&A session.
A preliminary program for the event is outlined below. To register, please click here.
Preliminary Agenda (times in
CET)
13:00 Introduction -Richard Godfrey, Chief Executive Officer,
BerGenBio
--- ---
AXL in AML/MDS
-Professor Sonja
Loges, Director, Department of Personalised Oncology,
University Hospital Mannheim and Division of Personalised
Medical Oncology, German Research Center -DKFZ
13:10 (Heidelberg, Germany)
13:40 AXL in lung cancer
-Dr Matthew Krebs, Clinical
Senior Lecturer in Experimental Cancer Medicine and
Honorary Consultant in Medical Oncology, The Christie NHS
Foundation Trust (Manchester, UK)
14:10 AXL and viruses/COVID-19
- Professor Wendy
Maury, Professor of Microbiology and Immunology, University
of Iowa (Iowa City, USA)
14:40 AXL in fibrosis/IPF
-
Professor Cory Hogaboam, Professor of
Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)
--- ---
15:10 Bemcentinib clinical development plan -Hani Gabra, Chief
Medical Officer, BerGenBio
15:25 Concluding remarks -Richard Godfrey, Chief Executive
Officer, BerGenBio
--- ---
For further information, please contact Consilium Strategic
Communications at bergenbio@consilium-comms.com or
ir@bergenbio.com
---
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA\
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-virtual-r-d-day---06-november-2020,c3221309
The following files are available for download:
https://mb.cision.com/Main/15728/3221309/1322984.pdf
Release
View original content:http://www.prnewswire.com/news-releases/bergenbio-virtual-rd-day--06-november-2020-301158567.html
SOURCE BerGenBio ASA
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
